ODDO BHF Initiates the Coverage of Aelis Farma With a “Buy” Recommendation
11 April 2022 - 6:13PM
Business Wire
Regulatory News:
Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a
clinical-stage biopharmaceutical company specialized in the
development of treatments for brain diseases (the « Company
»), announces today the publication of an initiation report by ODDO
BHF, one of Europe's leading independent financial services
companies specialising in research, execution and advisory.
In the initiation report, published on April 7, 2022, ODDO BHF
initiates the coverage of the stock with a buy recommendation and
values the company at 25 euros per share.
***
Next financial event:
Annual General Meeting: June 28, 2022
About ODDO BHF
ODDO BHF is an independent Franco-German financial services
group, with a history stretching back over 170 years. It was
created from the alliance of a French family-owned business built
up by five generations of stockbrokers and a German bank
specialising in Mittelstand companies. With 2,500 employees (1,300
in Germany and Switzerland and 1,200 in France and Tunisia), and
more than 125 billion euros in assets under management, ODDO BHF
operates in three main businesses, based on significant investment
in market expertise: private banking, asset management and
corporate and investment banking. The Group has a specific
ownership structure as 65% of its capital is held by the Oddo
family and 25 % by employees. This “partnership” ethos guarantees
the long-term involvement of its teams. In 2020, ODDO BHF generated
net banking income of 624 million euros, and at 31 December 2020,
the Group had over 940 million euros of shareholders' equity.
For more information: www.oddo-bhf.com
About AELIS FARMA
Founded in 2013, Aelis Farma is a biopharmaceutical company that
is developing a new class of drugs, the Signaling Specific
inhibitors of the CB1 receptor of the endocannabinoid system
(CB1-SSi). These new molecules hold great potential in the
treatment of many brain diseases. CB1-SSi were developed by Aelis
Farma on the basis of the discovery of a new natural defense
mechanism of the brain made by the team of Dr. Pier Vincenzo
Piazza, CEO of the Company, when he was Director of the Inserm
Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza
was awarded the Grand Prix of Inserm, and the Grand Prix of
Neurology of the French Academy of Sciences, which are among the
most prestigious French awards for medicine and neurology.
Aelis Farma is developing two first-in-class drug candidates
that are at the clinical stage, AEF0117 and AEF0217, and has a
portfolio of innovative CB1-SSi for the treatment of other diseases
associated with dysregulation of CB1 receptor activity.
AEF0117, which targets the disorders due to excessive cannabis
use (addiction and psychosis), has demonstrated efficacy in a phase
2a clinical trial and will enter a phase 2b clinical trial in the
United States in 2022. Aelis Farma has an exclusive option license
agreement with Indivior PLC, a leading pharmaceutical company in
the treatment of addiction, for the development and
commercialization of AEF0117 for disorders due to excessive
cannabis use. As part of this agreement, Aelis Farma received $30
million (option payment). If Indivior exercises the license option
at the end of the phase 2b, Aelis Farma will receive a $100 million
license fee (potentially in 2024) and up to $340 million in
additional payments contingent on the achievement of development,
regulatory and commercial milestones, as well as royalties on net
sales of AEF0117 ranging between 12% and 20%.
AEF0217, which targets various cognitive disorders including
those associated with Down syndrome, is progressing successfully in
its phase 1/2 program and could provide the first proof of efficacy
in early 2023. This compound has undergone an extensive preclinical
proof-of-concept program using highly innovative and highly
predictive tests to assess cognitive functions. In this context,
AEF0217 has demonstrated its ability to completely reverse deficits
in several models of cognitive disorders such as Down syndrome and
Fragile X syndrome, as well as in models of certain cognitive
deficits associated with aging.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis
Farma has a team of 24 highly qualified employees and has benefited
from investments from the Nouvelle-Aquitaine Region, Inserm
Transfert Initiative, Bpifrance, regional funds ACI, NACO and
Aqui-invest and IRDI Capital Investissement.
For more information: www.aelisfarma.com
Avertissement
Prospective Data
Some information contained in this press release are
forward-looking statements, not historical data. These
forward-looking statements are based on current beliefs,
expectations, and assumptions, including, but not limited to,
assumptions about Aelis Farma's current and future strategy and the
environment in which Aelis Farma operates. They involve known and
unknown risks, uncertainties, and other factors, which may cause
actual results, performance or achievements, or industry results or
other events, to differ materially from those described or implied
by such forward-looking statements. These risks and uncertainties
include those set out and detailed in Chapter 3 "Risk Factors" of
Aelis Farma's registration document approved by the Autorité des
marchés financiers on 14 January 2022 under number I.22-003.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220411005750/en/
AELIS FARMA Pier Vincenzo Piazza Co-founder and CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Marine de Fages Investor Relations
aelis@newcap.eu +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
nmerigeau@newcap.fr +33 1 44 71 94 98
Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024